Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 16/20 | 0.40 |
| ▸ | OXTR | P30559 | 4/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.35 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679299 | 1.00 | AVPR1B (0.40) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2680531 | 0.94 | AVPR1B (0.40) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2679972 | 0.94 | AVPR1B (0.40) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2678838 | 0.93 | AVPR1B (0.45) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2679018 | 0.93 | AVPR1B (0.45) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2678994 | 0.89 | AVPR1B (0.41) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2679392 | 0.89 | AVPR1B (0.41) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2679404 | 0.85 | AVPR1B (0.56) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2678987 | 0.85 | AVPR1B (0.56) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2680157 | 0.82 | AVPR1B (0.38) | AVPR1BOXTRAVPR1AAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-05-10 | — | — | US | disclosed |
| EP-1831197-A2 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006072458-A2 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885OXTR 1/4885AVPR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.